

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE, SCISEARCH' ENTERED AT  
12:17:39 ON 12 MAY 2003

L1	25350 S FASL OR FAS-LIGAND
L2	83 S FAS-ASSOCIATED PROTEIN WITH DEATH DOMAIN
L3	3332 S L2 OR FADD OR MORT-1
L4	710 S L1 AND L3
L5	1340 S DRACHMAN D?/AU
L6	9 S L4 AND L5
L7	5 DUP REM L6 (4 DUPLICATES REMOVED)
L8	45 S L4 AND VECTOR
L9	1 S L8 AND ANTIGEN-PRESENTING CELL
L10	22 DUP REM L8 (23 DUPLICATES REMOVED)
L11	1 S L10 AND PY<1997
L12	44 S L1 AND ANTIGEN-PRESENTING CELL AND AUTOIMMUNE
L13	34 DUP REM L12 (10 DUPLICATES REMOVED)
L14	0 S L13 AND PY<1997

L Number	Hits	Search Text	DB	Time stamp
1	3	"wo 9618641"	USPAT; EPO; JPO; DERWENT	2003/05/12 12:29
6	3	"wo 9618641" and fas	USPAT; EPO; JPO; DERWENT	2003/05/12 12:46
11	3	fas-L and fadd	USPAT; EPO; JPO; DERWENT	2003/05/12 12:51
16	3	fas-L and fadd and vector	USPAT; EPO; JPO; DERWENT	2003/05/12 12:50
21	0	fas-L same fadd	USPAT; EPO; JPO; DERWENT	2003/05/12 12:51
26	0	fas-L same mort-1	USPAT; EPO; JPO; DERWENT	2003/05/12 12:51
31	4	fas-L and (APC or antigen-presenting)	USPAT; EPO; JPO; DERWENT	2003/05/12 12:51
-	3777	myasthenia with gravis	USPAT; EPO; JPO; DERWENT	2003/05/12 12:29
-	12752	((435/320.1 or 424/93.21).CCLS.	USPAT; EPO; JPO; DERWENT	2002/09/09 19:37
-	0	("dendritic and 6 and antigen").PN.	USPAT; EPO; JPO; DERWENT	2002/09/09 19:38
-	0	("dendritic and 6").PN.	USPAT; EPO; JPO; DERWENT	2002/09/09 19:38
-	288	dendritic and ((435/320.1 or 424/93.21).CCLS.) and antigen	USPAT; EPO; JPO; DERWENT	2002/09/13 14:40
-	139	dendritic same antigen and ((435/320.1 or 424/93.21).CCLS.)	USPAT; EPO; JPO; DERWENT	2002/09/09 19:54
-	1015	Fas with ligand or FADD or CTLA4	USPAT; EPO; JPO; DERWENT	2003/05/08 11:05
-	17	T and (dendritic same antigen and ((435/320.1 or 424/93.21).CCLS.) ) and (Fas with ligand or FADD or CTLA4)	USPAT; EPO; JPO; DERWENT	2002/09/09 19:42
-	605387	@rlad<19971204	USPAT; EPO; JPO; DERWENT	2002/09/10 18:03
-	6	((T and (dendritic and ((435/320.1 or 424/93.21).CCLS.) and antigen) and (Fas with ligand or FADD or CTLA4)) and @rlad<19971204) and autoimmune	USPAT; EPO; JPO; DERWENT	2002/09/09 19:44
-	3	((T and (dendritic and ((435/320.1 or 424/93.21).CCLS.) and antigen) and (Fas with ligand or FADD or CTLA4)) and @rlad<19971204) and (myasthenia with gravis)	USPAT; EPO; JPO; DERWENT	2002/09/09 19:51
-	3	dendritic and ((435/320.1 or 424/93.21).CCLS.) and ((myasthenia with gravis) and (Fas with ligand or FADD or CTLA4) and @rlad<19971204)	USPAT; EPO; JPO; DERWENT	2002/09/09 19:54
-	32	(myasthenia with gravis) and (Fas with ligand or FADD or CTLA4) and @rlad<19971204	USPAT; EPO; JPO; DERWENT	2002/09/09 20:04
-	9193	activated with T	USPAT; EPO; JPO; DERWENT	2002/09/10 18:04
-	27	((myasthenia with gravis) and (Fas with ligand or FADD or CTLA4) and @rlad<19971204) and (activated with T)	USPAT; EPO; JPO; DERWENT	2002/09/09 20:05



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	<input checked="" type="checkbox"/> for						Go	Clear
Limits		Preview/Index		History		Clipboard		Details

Display	Abstract	<input checked="" type="checkbox"/> Show: 20	<input checked="" type="checkbox"/> Sort	<input checked="" type="checkbox"/> Send to	Text	<input checked="" type="checkbox"/>
---------	----------	--	--	---	------	-------------------------------------

Entrez  
PubMed

☐ 1: Hum Gene Ther 2000 Apr 10;11(6):851-8

[Related Articles, Links](#)



## Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand.

Georgantas RW 3rd, Leong KW, August JT.

PubMed  
Services

Department of Pharmacology and Molecular Science, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Related  
Resources

Fas ligand (FasL, CD95L) induces apoptosis in activated T cells with upregulated Fas (CD95) expression through the process termed activation-induced cell death (AICD). We postulated that coexpression of antigen and FasL within individual antigen-presenting cells would lead to antigen-specific activation of T cells and to their consequent deletion by FasL-mediated AICD. A DNA-gelatin coacervate containing transferrin cell ligand, calcium, and the lysosomotropic agent chloroquine, a formulation previously shown to achieve high-level transfection of immune and muscle cells in vivo, was used to codeliver plasmids encoding FasL and antigen. Mice developed a strong cytolytic T cell response to beta-Gal when injected with DNA encoding beta-galactosidase (LacZ) model antigen, either as naked DNA or DNA nanoparticles, but failed to respond when there was concomitant injection of nanoparticles containing both the LacZ and murine FasL DNA vectors. This loss of T cell response was systemic, specific for beta-Gal, complete when nanoparticles were administered before antigen challenge, and decreased the T cell response from prior immunization with LacZ DNA. In effect, this "tolerization" injection induced antigen-specific peripheral tolerance in study mice, and represents a possible approach to the treatment of autoimmune diseases and transplantation rejection.

PMID: 10779162 [PubMed - indexed for MEDLINE]

Display	Abstract	<input checked="" type="checkbox"/> Show: 20	<input checked="" type="checkbox"/> Sort	<input checked="" type="checkbox"/> Send to	Text	<input checked="" type="checkbox"/>
---------	----------	--	--	---	------	-------------------------------------

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

May 2 2003 16:34:23